Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895414 · ClinicalTrials.gov registry record · NA
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT00895414 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 19 participants.
The verdict
NCT00895414, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enalapril maleate may help protect heart cells from the side effects of chemotherapy. It is not yet known whether giving enalapril maleate before or after doxorubicin hydrochloride is more effective in treating women with breast cancer. PURPOSE: This randomized clinical trial is studying giving enalapril maleate together with doxorubicin hydrochloride to see how well it works in treating women with breast cancer.
Interventions
- DRUG doxorubicin hydrochloride
- DRUG enalapril maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-04 |
| Est. Completion | 2015-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00895414
The ClinicalTrials.gov registry entry for NCT00895414 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which doxorubicin hydrochloride is the first listed.
NCT00895414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00895414 about?
NCT00895414 is a clinical study titled "Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enalapril maleate may help protect heart cells from the side effects of chemotherapy. It is not yet known...
What is the current status of trial NCT00895414?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2009-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00895414?
The interventions under investigation include: doxorubicin hydrochloride (DRUG), enalapril maleate (DRUG).
Who is sponsoring clinical trial NCT00895414?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.